Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3331716 | Hematology/Oncology Clinics of North America | 2010 | 16 Pages |
Abstract
Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage. There are limited data regarding hydroxyurea's ability to prevent or diminish organ dysfunction, and the long-term risks of hydroxyurea therapy remain incompletely defined. Although clinical trials are underway to address long-term issues, hydroxyurea remains an effective but underutilized therapy for SCD.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Matthew M. Heeney, Russell E. Ware,